Intensive rosuvastatin therapy leads to regression of atherosclerosis

This article has no abstract so we have provided the first paragraph of the full text.

Trials of atherosclerosis treatments have demonstrated halting of disease progression, as measured by intravascular ultrasound, but convincing evidence of regression has not been obtained. High-intensity statin therapy has had a more beneficial effect on cardiovascular outcomes than has been seen with more-moderate treatment. The prospective, open-label, blinded ASTEROID trial was, therefore, initiated to test the hypothesis that intensive rosuvastatin therapy, designed to achieve very low levels of LDL cholesterol, would lead to regression of atherosclerosis as evaluated by intravascular ultrasound, particularly if a substantial increase in HDL cholesterol was also obtained.

ARTICLE NAVIGATION - ARTICLE TOOLS

• Full text
• Download PDF
• Send to a friend
• PDA services
• Permissions
• Rights and permissions
• Order commercial reprints

ISSUE NAVIGATION - THIS ISSUE

• Table of Contents
• Previous article
• Next article